Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3352W HIGH $3.10
Volume
1.16 M
Value Traded
939.16 K
Short % Float
2.45%
-3.98%Week
-21.11%1 Month
-9.25%3 Month
-15.14%6 Month
-75.66%5 Year
-92.16%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
221.56 M
EPS (TTM)
-0.50
P/E Ratio
-
Ent. Value
86.70 M
Total Shares
141.12 M
Float Shares
98.25 M
Insiders
28.85%
Institutions
44.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PRQR Catalyst Timeline
Dated clinical, regulatory and corporate events for ProQR Therapeutics N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProQR Therapeutics N.V.
830Total events
24Upcoming
148Tier-1 (high impact)
2014 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedAX-0811Trial
First participant dosed in Phase 1 study of AX-0811
cholestatic liver diseases, including biliary atresiasource ↗
●Trial InitiationAX-0811Trial
CTA submitted to EMA for AX-0811 Phase 1 trial
cholestatic diseasessource ↗
▲Topline ReadoutAX-0810Clinical Data
Positive Phase 1 target engagement data for AX-0810 in healthy volunteers
cholestatic liver diseasessource ↗
▼Equity OfferingCorporate
Closed underwritten registered direct offering and private placement for $59.2 million
◆Poster PresentationPresentation
RNA Society Annual Meeting poster on Axiomer platform advancements
◆Oral PresentationPresentation
ASGCT 29th Annual Meeting oral presentation on AX-2911 in MASLD/MASH
◆Oral PresentationPresentation
ASGCT 29th Annual Meeting oral presentation on AX-2402 in Rett syndrome
◆Oral PresentationPresentation
TIDES USA 2026 oral presentation on Axiomer pipeline programs and AX-0422
●Oral PresentationPresentation
Presentations at TIDES USA, ASGCT, RNA Society, and EASL Congress
◆R&D DayPresentation
Virtual Investor and Analyst Event: Expanding the Axiomer RNA Editing Opportunity Beyond AX-0810
▲Partnership / LicenseCorporate
Partnership with Ginkgo Bioworks for autonomous lab high throughput data generation
◆Topline ReadoutAX-0810Clinical Data
Initial clinical data from Phase 1 study of AX-0810 in healthy volunteers
cholestatic diseasessource ↗
◆Oral PresentationPresentation
ProQR management presentation at Citizens Life Sciences Conference
▲Topline ReadoutAX-0810Clinical Data
Initial safety and PK data from Cohort 1 (3mg/kg) of AX-0810 Phase 1 trial
cholestatic diseasessource ↗
▲Partnership / LicenseCorporate
Partnership with Ginkgo Bioworks for high-throughput data generation
◆Topline ReadoutAX-0810Clinical Data
Safety, tolerability, and PK data from Cohort 1 expected
cholestatic diseasessource ↗
●Oral PresentationAX-0810Presentation
Virtual Investor and Analyst Event on AX-0810 Phase 1 study
cholestatic diseases (primary sclerosing cholangitis, biliary atresia)source ↗
▲IND ClearanceAX-0810IND
CTA approved for first-in-human trial of AX-0810 in Europe
cholestatic diseasessource ↗
▲First Patient DosedAX-0810Trial
First patient dosed in FIH trial of AX-0810
cholestatic diseasessource ↗
▲IND ClearanceAX-0810IND
CTA authorized for Phase 1 study of AX-0810 in healthy volunteers
cholestatic diseases (primary sclerosing cholangitis, biliary atresia)source ↗
▲First Patient DosedAX-0810Trial
First patient dosing expected in Phase 1 study of AX-0810
cholestatic diseases (primary sclerosing cholangitis, biliary atresia)source ↗
◆Oral PresentationPresentation
ProQR management to participate in upcoming investor conferences in October 2025
▲Trial InitiationAX-0810Trial
First-in-human study initiated for AX-0810
NTCP for cholestatic diseasessource ↗
▲First Patient DosedAX-0810Trial
First patient dosed in Phase 1 study of AX-0810
NTCP for cholestatic diseasessource ↗
▲Trial Authorization (CTA / IND)AX-0810Ex-US Regulatory
AX-0810 CTA approved in Europe
Cholestatic diseasessource ↗
◆Topline ReadoutAX-0810Clinical Data
First clinical target engagement and biomarker data in healthy volunteers for AX-0810
Cholestatic diseasessource ↗
◆Oral PresentationPresentation
Presentation at RNA Editing Summit featuring preclinical NHP data in CNS and Rett program targeting MECP2
▲IND SubmissionAX-0810IND
CTA submission for AX-0810 targeting NTCP for cholestatic diseases
cholestatic diseasessource ↗
◆Trial InitiationAX-0810Trial
Phase 1 study expected to commence pending regulatory clearance
cholestatic liver diseasesource ↗
●EU MAA SubmissionAX-0810Ex-US Regulatory
CTA submission to EMA for Phase 1 study of AX-0810
cholestatic liver diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How PRQR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-14 | AX-2402 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 77%
Micro Cap(rank 507 of 658)
Percentile Rank
ProQR Therapeutics N.V. faces pipeline headwinds (27/100), with $16M risk-adjusted pipeline value, with 2 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| QR-421a Small moleculeCompletedNCT03780257 | Retinitis Pigmentosa | Phase 1 | COMPLETED | 20 | Oct 14, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRQR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AX-0810 | biliary atresia | Phase 1 | 2026-06-25 | up to 8-fold change (6 mg/kg) in total bile acids in serum; exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulationRead More | ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| de Boer Daniel AntonDirector, Officer (Chief Executive Officer) | Buy | 200,000 500,000 held | $1.77 | 07/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRQR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.5 % (150 %) | 10.31 M | 5.54 M | 125.89% ( 3.09 M) |
PRQR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRQR ranks across every disease it competes in
Competitive Position is a premium feature
See how PRQR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRQR News
PRQR▼ -10.5%on this news
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
ProQR Therapeutics has appointed Chris Hart as Chief Data and AI Officer and Thomas Wolf as a strategic AI advisor to its Board of Directors. These appointments aim to enhance ProQR's AI strategy, particularly in the development of its Axiomer RNA editing platform. The company anticipates significant clinical data readouts over the next year, demonstrating the potential of AI in accelerating drug discovery.
Read more →PRQRProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
ProQR Therapeutics has announced the dosing of the first participant in its Phase 1 trial for AX-0811, an investigational RNA editing oligonucleotide aimed at treating cholestatic liver diseases. The trial will assess safety and pharmacokinetics, building on previous data from AX-0810. Additionally, a virtual educational event is scheduled for September 30, 2026, to discuss the implications of NTCP modulation in biliary atresia.
Read more →PRQRProQR to Participate in Upcoming Investor Conferences in September 2026
ProQR Therapeutics will participate in two upcoming investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. The company is focused on its Axiomer RNA editing technology, which aims to develop transformative therapies for various diseases. Webcast details will be available on their website.
Read more →PRQRProQR Announces Second Quarter 2026 Operating and Financial Results
ProQR Therapeutics reported positive clinical validation for its Axiomer RNA editing platform, with promising AX-0810 data indicating effective NTCP modulation. The company anticipates multiple clinical milestones, including initial data from AX-0811 and the initiation of a biliary atresia trial. ProQR also strengthened its financial position with a $59.2 million financing round.
Read more →PRQR▼ -13.5%on this news
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
ProQR Therapeutics has announced a successful pricing of a $50 million underwritten registered direct offering of ordinary shares at $1.81 each. Concurrently, Eli Lilly will purchase additional shares to maintain its ownership stake, contributing approximately $9.2 million. The proceeds will primarily support research and clinical development of ProQR's RNA therapies. The offering is expected to close on June 26, 2026.
Read more →PRQR▼ -13.5%on this newsshared move
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
ProQR Therapeutics announced positive Phase 1 data for AX-0810, showing significant target engagement in healthy volunteers. The study demonstrated dose-dependent increases in total bile acids, exceeding the predefined threshold for NTCP modulation. AX-0810 exhibited a favorable safety profile with no serious adverse events reported. The findings support further development of AX-0811 for biliary atresia.
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at
PROQR Therapeutics N.V. has reported its financial results for the first quarter of 2026, revealing a comprehensive loss of €13.2 million, which is an increase from a €10.5 million loss in the same period last year. The company’s revenue fell sharply to €2.0 million compared to €4.5 million in Q1 2025. Operating costs also rose, affecting the overall financial performance negatively. With equity declining from €49.4 million to €37.6 million since the previous quarter, concerns over financial stability are evident.
Read more →PRQRProQR Announces First Quarter 2026 Operating and Financial Results
ProQR Therapeutics reported its Q1 2026 results, highlighting progress in its RNA editing pipeline, including the upcoming target engagement data for AX-0810 in biliary atresia. The company is expanding its pipeline with AX-0811 and AX-0422, while maintaining a strong cash position of €81.1 million. ProQR is also enhancing its Axiomer platform through AI partnerships and has nominated a new board member.
Read more →PRQRProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
ProQR Therapeutics has announced several upcoming presentations at scientific conferences, showcasing advancements in its Axiomer RNA editing platform. The presentations will cover various applications, including treatments for Hurler syndrome and Rett syndrome. The company anticipates initial clinical data for its lead program, AX-0810, in healthy volunteers later this quarter.
Read more →PRQR▲ +5.8%on this news
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
ProQR Therapeutics has announced its Annual General Meeting (AGM) of Shareholders scheduled for June 2, 2026, in Amsterdam. The meeting will cover important company updates and provide shareholders with access to relevant documents via the company's website. ProQR continues to develop its Axiomer RNA editing technology, which aims to create new therapies for various diseases.
Read more →PRQRProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
ProQR Therapeutics has nominated Dr. Lykke Hinsch Gylvin to its Board of Directors. Dr. Gylvin, currently the Chief Medical Officer at Boehringer Ingelheim, brings extensive experience in drug development. Her nomination will be submitted for shareholder approval at the upcoming Annual General Meeting. If approved, she will serve as an independent non-executive director.
Read more →PRQR▲ +7.6%on this news
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
ProQR Therapeutics highlighted significant updates on its RNA editing pipeline during a recent Investor and Analyst event. The company announced progress on its lead program AX-0810, which is due to report target engagement data soon, and introduced new programs AX-0811 and AX-0422 aimed at treating cholestatic diseases and Hurler syndrome, respectively. The event underscored the strength of ProQR's proprietary Axiomer platform and projected multiple upcoming clinical data readouts, indicating a robust path forward in their development strategy.
Read more →PRQR▲ +7.6%on this news
EXPANDING THE AXIOMER RNA EDITING OPPORTUNITY BEYOND AX-0810 Nasdaq: PRQR |
ProQR Therapeutics is expanding its Axiomer RNA editing platform, focusing on the development of AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) and AX-0422 for Hurler Syndrome. AX-2911 has shown promising preclinical results, including a significant reduction in liver fat. Furthermore, the company is planning to initiate clinical trials for both therapies, aiming for first-in-human trials in 2027. This expansion underscores ProQR's strategic focus on addressing critical unmet medical needs in various conditions.
Read more →PRQR▲ +7.6%on this news
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
ProQR Therapeutics has announced a partnership with Ginkgo Bioworks to enhance its AI-enabled drug discovery efforts using high-throughput data generation. Additionally, the company has formed an AI Advisory Board comprising industry experts to guide its AI strategy. ProQR expects to advance its first AI-discovered Development Candidate into clinical trials by 2026.
Read more →PRQR▲ +6%on this news
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
ProQR Therapeutics will host a virtual Investor and Analyst Event on April 8, 2026, to discuss its RNA editing pipeline, including the anticipated data for AX-0810. The event will feature presentations and a Q&A session, highlighting new clinical programs and the primary indication for AX-0810. ProQR aims to showcase its transformative RNA therapies and the potential of its Axiomer technology.
Read more →PRQRProQR Announces Year End 2025 Operating and Financial Results
ProQR Therapeutics reported its 2025 financial results, highlighting significant progress in its clinical pipeline, including the advancement of AX-0810 into Phase 1 trials. The company achieved collaboration milestones with Eli Lilly and selected new development candidates for Rett syndrome and MASH. However, it also reported an increase in net loss and a decrease in cash reserves compared to the previous year.
Read more →PRQR▲ +13.3%on this news· ran to +26% by day 3
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
ProQR Therapeutics N.V. has announced that its management will present at the Citizens Life Sciences Conference on March 11, 2026. The presentation will highlight the company's innovative Axiomer™ RNA editing technology, which aims to develop new treatments for diseases by making precise edits to RNA. A live webcast of the presentation will be available on ProQR's website.
Read more →PRQRProQR Announces Planned Changes to Board Composition
ProQR Therapeutics announced planned changes to its Board composition, with co-founder Dinko Valerio and Alison Lawton rotating off at the upcoming AGM. This decision reflects the company's growth and commitment to corporate governance. An executive search firm has been engaged to identify new candidates for the Board to enhance long-term value creation.
Read more →PRQRProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
ProQR Therapeutics has announced positive initial data from its Phase 1 trial of AX-0810, indicating no safety concerns after four weeks of dosing. The company also provided updates on selected development candidates for AX-2402 and AX-2911, targeting Rett syndrome and metabolic liver disease, respectively. Additionally, ProQR highlighted a successful collaboration with Eli Lilly, which achieved significant financial milestones in 2025. Looking ahead to 2026, ProQR aims to advance its pipeline and provide further target engagement data for AX-0810.
Read more →PRQR▼ -9.4%on this news
ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference on December 4, 2025. The company is focused on its Axiomer RNA editing technology, which aims to create new medicines for diverse diseases. Webcast details will be available on ProQR's website, and archived webcasts will be accessible for 30 days post-event.
Read more →About ProQR Therapeutics N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next PRQR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime